Emmaus Life Sciences' Real World Data on Endari® Accepted for E-Poster at the 62nd Annual Scientific Meeting of the British Society for Haematology

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...

Related Keywords

Qatar ,Doha ,Ad Daw Ah ,United States ,United Kingdom ,Manchester ,France ,French Guiana ,Americans ,British ,Randa Alokka ,Gylna Loko ,Maryse Etienne Julan ,Mohamed Yassin ,Ahmad Adel ,Narcisse Elenga ,Research Publications ,Centers For Disease ,Committee On Addressing Sickle Cell Disease ,Prnewswire Emmaus Life Sciences Inc ,National Centre For Cancer Care ,Drug Administration ,Hamad Medical Corporation ,National Center On Birth Defects ,Blueprint For Action National Academy Of Sciences ,Emmaus Life Sciences ,Meeting Of The British Society For Haematology ,Emmaus Life Sciences Inc ,Life Sciences ,Annual Meeting ,British Society ,Manchester Central ,Real World Data ,Pharmaceutical Gradel Glutamine ,Poster Number ,Fort De France ,National Centre ,Cancer Care ,Medical Corporation ,In Person Manchester Central ,Prescribing Information ,Sickle Cell Disease ,National Center ,Birth Defects ,Developmental Disabilities ,Disease Control ,Addressing Sickle Cell Disease ,Strategic Plan ,Sciences Press ,Middle East North Africa ,Nc ,